Search

Dry eye disease (DED) is a chronic multifactorial disorder of the ocular surface caused by tear film dysfunction and constitutes one of the most common ocular conditions worldwide. However, its treatment remains unsatisfactory. While artificial tears are commonly used to moisturize the ocular surface, they do not address the underlying causes of DED. Apigenin (APG) is a natural product with anti-inflammatory properties, but its low solubility and bioavailability limit its efficacy. Therefore, a novel formulation of APG loaded into biodegradable and biocompatible nanoparticles (APG-NLC) was developed to overcome the restricted APG stability, improve its therapeutic efficacy, and prolong its retention time on the ocular surface by extending its release. APG-NLC optimization, characterization, biopharmaceutical properties and therapeutic efficacy were evaluated. The optimized APG-NLC exhibited an average particle size below 200 nm, a positive surface charge, and an encapsulation efficiency over 99 %. APG-NLC exhibited sustained release of APG, and stability studies demonstrated that the formulation retained its integrity for over 25 months. In vitro and in vivo ocular tolerance studies indicated that APG-NLC did not cause any irritation, rendering them suitable for ocular topical administration. Furthermore, APG-NLC showed non-toxicity in an epithelial corneal cell line and exhibited fast cell internalization. Therapeutic benefits were demonstrated using an in vivo model of DED, where APG-NLC effectively reversed DED by reducing ocular surface cellular damage and increasing tear volume. Anti-inflammatory assays in vivo also showcased its potential to treat and prevent ocular inflammation, particularly relevant in DED patients. Hence, APG-NLC represent a promising system for the treatment and prevention of DED and its associated inflammation.

Este artículo presenta una visión del uso de las redes de polímeros orgánicos porosos (POPs) como catalizadores heterogéneos eficientes y fácilmente reciclables en una amplia diversidad de transformaciones químicas, especialmente en organocatálisis, tanto en operaciones por lotes (batches) como en operaciones en continuo de larga duración. Estos catalizadores heterogéneos pueden obtenerse fácilmente por incorporación del catalizador orgánico o metálico en las estructuras de los POPs a través de diversas estrategias. Además, la posibilidad de usarlos en operaciones en continuo es clave para que estos materiales sean considerados sostenibles y puedan ser utilizados a escala industrial. En el ámbito de la catálisis asimétrica, la preparación de nuevos catalizadores quirales que permitan discriminar enantiómeros selectivamente para obtener numerosos productos de alto valor añadido o biológicamente activos es de gran interés, y más si tecnológicamente pueden emplearse en la química de flujo., This work provides an overview about the use of porous organic polymers (POPs) networks as efficient and easily recyclable heterogeneous catalysts in a wide diversity of chemical transformations, especially in organocatalysis, both in batch operations and in long-duration continuous flow processes. These heterogeneous catalysts can be easily obtained by incorporating the organic or metallic catalyst in the structures of POPs through different strategies. Furthermore, the possibility of using these heterogeneous catalysts in continuous operations is a key approach for these materials to be considered sustainable and they can be used on an industrial scale. In the field of asymmetric catalysis, the preparation of new chiral catalysts that allow enantiomers to be selectively discriminated to obtain numerous products with high added value or biologically activity is highly sought after, and even more so if they can be used in flow chemistry processes

Asphalt is an essential material in the construction of asphalt pavements. Due to its high demand and dependence on petroleum, it is crucial to use greener materials that can fully or partially replace petroleum-based binders. The characteristics of asphalt cause the bio-binder obtained through a hydrothermal liquefaction process from swine manure to have great potential to be used as a modifier due to its similarities with asphalt, contributing to the construction of more sustainable roads. Thus, this paper characterizes an asphalt binder modified with a new bio-binder obtained from swine manure at different rates (0%, 10%, and 20%). Several characterization tests were performed, including penetration, ring and ball, Fraass, viscosity, Cleveland open cup, and the UCL method. Furthermore, the possible leaching of the bio-binder was studied, showing no environmental problems. Results from the rheological tests showed that as the content of bio-binder increases, the softening temperature, Fraass breaking point, and viscosity of the bio-modified asphalt binder decrease, indicating the lower consistency of the bio-modified binder and its greater thermal susceptibility.

Background: In the SOLO2 trial (ENGOT Ov-21; NCT01874353), maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and BRCA mutation significantly improved progression-free survival (PFS) and prolonged overall survival (OS). Following disease progression on olaparib, efficacy of subsequent chemotherapy remains unknown. Patients and methods: We conducted a post-hoc hypothesis-generating analysis of SOLO2 data to determine the efficacy of different chemotherapy regimens following RECIST disease progression in patients who received olaparib or placebo. We evaluated time to second progression (TTSP) calculated from the date of RECIST progression to the next progression/death. Results: The study population comprised 147 patients who received chemotherapy as their first subsequent treatment after RECIST progression. Of these, 69 (47%) and 78 (53%) were originally randomized to placebo and olaparib arms, respectively. In the placebo-treated cohort, 27/69 and 42/69 received non-platinum and platinum-based chemotherapy, respectively, compared with 24/78 and 54/78, respectively, in the olaparib-treated cohort. Among patients treated with chemotherapy (N = 147), TTSP was significantly longer in the placebo than in the olaparib arm: 12.1 versus 6.9 months [hazard ratio (HR) 2.17, 95% confidence interval (CI) 1.47-3.19]. Similar result was obtained on multivariable analysis adjusting for prognostic factors at RECIST progression (HR 2.13, 95% CI 1.41-3.22). Among patients treated with platinum-based chemotherapy (n = 96), TTSP was significantly longer in the placebo arm: 14.3 versus 7.0 months (HR 2.89, 95% CI 1.73-4.82). Conversely, among patients treated with non-platinum-based chemotherapy (n = 51), the TTSP was comparable in the placebo and olaparib arms: 8.3 versus 6.0 months (HR 1.58, 95% CI 0.86-2.90). Conclusions: Following progression from maintenance olaparib in the recurrent setting, the efficacy of platinum-based subsequent chemotherap